An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate and confirm hypoglycemic efficacy and safety of
CKD-501 as mono therapy in patients with type 2 diabetes treated once daily for 24 weeks in
comparison to placebo.